CP-MVC-101-01
20 Apr 2022
Trial Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics and preliminary antitumor activity of MVC-101
Acronym:
CP-MVC-101-01
ACTRN/NCT /ethics:
NCT04844073
Scientific title:
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study of MVC-101, An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA™) Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer
Sponsor / Cooperative group:
Takeda
Trial & Patient Characteristics
| Cancer Type | All cancers |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I; Phase II |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
| Anticipated Start Date | 2021-03-08 |
| Anticipated End Date | 2024-10-01 |
Participating Hospitals
| Hospital | Southern Oncology Clinical Research Unit |
|---|---|
| Clinical Trial Coordinator | Meggan O'Riley |
| Meggan.ORiley@socru.org.au | |
| Phone | 0491 679 039 |
| Principal Investigator | Dr Ganessan Kichenadasse |
| Recruitment Status | Recruiting |